Nom du produit:3-Amino-4,5-dimethylisoxazole

IUPAC Name:dimethyl-1,2-oxazol-3-amine

CAS:13999-39-8
Formule moléculaire:C5H8N2O
Pureté:97%
Numéro de catalogue:CM118957
Poids moléculaire:112.13

Unité d'emballage Stock disponible Prix($) Quantité
CM118957-1g in stock ȷƻ
CM118957-5g in stock ƻȌƻ
CM118957-25g in stock ƙǧſƱ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:13999-39-8
Formule moléculaire:C5H8N2O
Point de fusion:-
Code SMILES:CC1=C(C)C(N)=NO1
Densité:
Numéro de catalogue:CM118957
Poids moléculaire:112.13
Point d'ébullition:
N° Mdl:MFCD03411577
Stockage:

Category Infos

Isoxazoles
Isoxazole is a liquid heterocyclic compound C3H3NO isomeric with oxazole and having a penetrating odor like that of pyridine. Isoxazoles belong to an important class of five-membered aromatic heterocycles containing two electronegative heteroatoms, nitrogen and oxygen, in a 1,2-relationship and three regular sp2 carbon atoms. These molecules are found to be key components in various synthetic products in daily use and also present as a pharmacophore essential for biological activity in many drugs and bioactive natural products. In addition, isoxazoles have demonstrated their ability to exhibit hydrogen bond donor/acceptor interactions with a variety of enzymes and receptors.

Column Infos

Oxazoles
Oxazoles are heterocyclic aromatic compounds containing one oxygen atom and one nitrogen atom, separated by a carbon atom. The presence of two heteroatoms (oxygen and nitrogen) provides possible interactions (hydrogen, hydrophobic, van der Waals or dipole bonds) with a wide range of receptors and enzymes. Oxazole rings are valuable heterocyclic scaffolds for the design of novel therapeutics with anticancer, antiviral, antibacterial, anti-inflammatory, neuroprotective, antidiabetic, and antidepressant properties due to their wide range of targets and biological activities.
Sparsentan
CSL Vifor and Travere Therapeutics announce European Commission approves FILSPARI(sparsentan) for the treatment of IgA Nephropathy (IgAN). First non-immunosuppressive therapy for the treatment of IgAN approved in Europe.
Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist with high selectivity for the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease, protects podocytes, prevents glomerulosclerosis and mesangial cell proliferation, and reduces proteinuria. 

Related Products